Potential serum biomarkers in the pathophysiological processes of stroke

Expert Review of Neurotherapeutics

Volumn 14, Issue 2, 2014, Pages 173-185

  Miao, Yanying ^a   Liao, James K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

biomarkers; cerebral ischemia; clinical trial; pathophysiology; stroke

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALBUMIN; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; COPEPTIN; D DIMER; ENDOTHELIN 1; FIBRONECTIN; FREE RADICAL; GELATINASE B; HOMOCYSTEINE; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MICRORNA; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PENTRAXIN 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROENKEPHALIN; PROENKEPHALIN A; PROTEIN S100B; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ACIDOSIS; APOPTOSIS; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN VASOSPASM; CALCIUM CELL LEVEL; CARDIOEMBOLIC STROKE; CAUSE OF DEATH; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISABILITY; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; EXCITOTOXICITY; GLIA CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; LIPID OXIDATION; LIPID PEROXIDATION; NERVE CELL NECROSIS; NEUROIMAGING; NEUROSURGERY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; STROKE;

EID: 84893057460     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.875471     Document Type: Review

References (107)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371: 1612-23
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics- 2010 update: A report from the American Heart Association. Circulation 2010 121: E46-e215
3. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 2009;111(6): 483-95
4. Latchaw RE, Alberts MJ, Lev MH, et al. Recommendations for imaging of acute ischemic stroke: A scientific statement from the American Heart Association. Stroke 2009;40(11):3646-78
5. Jaffer H, Morris VB, Stewart D, Labhasetwar V. Advances in stroke therapy. Drug Deliv Transl Res 2011;1(6):409-19
6. Aldámiz-Echevarría L, Andrade F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci 2012;13(9):11288-311
7. Scherbakov N, Sandek A, Martens-Lobenhoffer J, et al. Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cerebrovasc Dis 2012;33:37-46
8. Worthmann H, Chen S, Martens-Lobenhoffer J, et al. High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. J Atheroscler Thromb 2011;18(9):753-61
9. Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010;208(2):518-23
10. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women:24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008;28(5):961-7
11. Brouns R, Marescau B, Possemiers I, et al. Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem Res 2009;34:1642-9
12. Jung CS, Oldfield EH, Harvey-White J, et al. Association of an endogenous inhibitor of nitric oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2007;107(5):945-50
13. Rueda-Clausen CF, Cordoba-Porras A, Bedoya G, et al. Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 2012;19:417-25
14. Pernow J, Shemyakin A, Bohm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 2012;91(13-14):507-16
15. Moldes O, Sobrino T, Millán M, et al. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. Stroke 2008;39(7):2006-10
16. Sapira V, Cojocaru IM, Lilios G, et al. Study of endothelin-1 in acute ischemic stroke. Rom J Intern Med 2010;48(4): 329-32
17. Haapaniemi E, Tatlisumak T, Hamel K, et al. Plasma endothelin-1 levels neither increase nor correlate with neurological scores, stroke risk factors, or outcome in patients with ischemic stroke. Stroke 2000; 31(3):720-5
18. Paczkowska E, Goła̧b-Janowska M, Bajer-Czajkowska A, et al. Increased circulating endothelial progenitor cells in patients with haemorrhagic and ischaemic stroke: The role of Endothelin-1. J Neurol Sci 2013;325(1-2):90-9
19. Valentijn KM, Sadler JE, Valentijn JA, et al. Functional architecture of Weibel-Palade bodies. Blood 2011;117(19): 5033-43
20. Andersson HM, Siegerink B, Luken BM, et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012;119(6):1555-60
21. Licata G, Tuttolomondo A, Di Raimondo D, et al. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 2009;101:929-371
22. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371: 1612-23
23. Yip HK, Lai SL, Lan MY, et al. Time course of platelet activation and von Willebrand factor in patients with non-valvular atrial fibrillation after ischemic stroke. Circ J 2007;71:321-6
24. Hanson E, Jood K, Karlsson S, et al. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011;9(2):275-81
25. Van De Craen B, Declerck PJ, Gils A. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012; 130(4):576-85
26. Abdullah WZ, Idris SZ, Bashkar S, Hassan R. Role of fibrinolytic markers in acute stroke. Singapore Med J 2009;50(6): 604-9
27. Haapaniemi E, Soinne L, Syrjala M, et al. Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke. Acta Neurol Scand 2004;110(4):242-7
28. Ilhan D, Ozbabalik D, Gulcan E, et al. Evaluation of platelet activation, coagulation, and fibrinolytic activation in patients with symptomatic lacunar stroke. Neurologist 2010;16(3):188-91
29. Meng R, Li ZY, Ji X, et al. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clin Neurol Neurosurg 2011;113(5):380-6
30. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry 2011;82(9):986-92
31. Hirano K, Takashima S, Dougu N. Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis 2012;21(5):404-10
32. Isenegger J, Meier N, Lammle B, et al. D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis 2010;29(1): 82-6
33. Park YW, Koh EJ, Choi HY. Correlation between serum D-dimer level and volume in acute ischemic stroke. J Korean Neurosurg Soc 2011;50(2):89-94
34. Sakaguchi M, Okazaki S. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation. Cerebrovasc Dis 2013;35(1):64-72
35. Hasan N, McColgan P, Bentley P, et al. Towards the identification of blood biomarkers for acute stroke in humans: A comprehensive systematic review. Br J Clin Pharmacol 2012;74(2):230-40
36. Yoon CW, Kim SJ, Bang OY, et al. Premorbid warfarin use and lower D-dimer levels are associated with spontaneous early improvement in atrial fibrillation-related stroke. J Thromb Haemost 2012;[Epub ahead of print]
37. Krarup LH, Sandset EC, Sandset PM, Berge E. D-dimer levels and stroke progression in patients with acute ischemic stroke and atrial fibrillation. Acta Neurol Scand 2011;124(1):40-4
38. Haapaniemi E, Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand 2009;119(3):141-50
39. Dougu N, Takashima S, Sasahara E, et al. Differential diagnosis of cerebral infarction using an algorithm combining atrial fibrillation and D-dimer level. Eur J Neurol 2008;15(3):295-300
40. Romi F, Helgeland G, Gilhus NE. Serum levels of matrix metalloproteinases: Implications in clinical neurology. Eur Neurol 2012;67(2):121-8
41. Castellanos M, Sobrino T, Millán M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke 2007;38(6): 1855-9
42. Bogoslovsky T, Spatz M, Chaudhry A, et al. Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients. J Transl Med 2011;9:145
43. Jaroslav P, Christian R, Stefan O, et al. Evaluation of serum biomarkers for patients at increased risk of stroke. Int J Vasc Med 2012;906954
44. Barr TL, Latour LL, Lee KY, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010; 41(3):e123-8
45. Silva Y, Leira R, Tejada J, et al. Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005;36(1):86-91
46. Serena J, Blanco M, Castellanos M, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005;36(9): 1921-6
47. Doehner W, von Haehling S, Suhr J, et al. Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J Am Coll Cardiol 2012;60(4):346-534
48. Jung JY, Lee HS, Kang DG, et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke 2011;42(5): 1282-8
49. Cui R, Iso H, Toyoshima H, et al. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis 2007;194:415-20
50. Tanabe N, Iso H, Okada K, et al. Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - The JALS-ECC. Circ J 2010;74:1346-56
51. Suzuki K, Izumi M, Sakamoto T, Hayashi M. Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita. Japan. Cerebrovasc Dis 2011;31(1):100-6
52. Cui R, Iso H, Yamagishi K, et al. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: The JPHC study. Atherosclerosis 2012;221(2):565-9
53. Powner DJ. In my opinion: Serum albumin should be maintained during neurocritical care. Neurocrit Care 2011;14(3):482-8
54. Babu MS, Kaul S, Dadheech S, et al. Serum albumin levels in ischemic stroke and its subtypes: Correlation with clinical outcome. Nutrition 2013;29(6):872-5
55. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Albumin level and stroke. Potential association between lower albumin level and cardioembolic aetiology. Int J Neurosci 2011;121(1):25-32
56. Idicula TT, Waje-Andreassen U, Brogger J, et al. Serum albumin in ischemic stroke patients: The higher the better. The Bergen Stroke Study. Cerebrovasc Dis 2009;28(1): 13-17
57. Ginsberg MD, Palesch YY, Martin RH, et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2. Stroke 2011;42(1):119-27
58. Dziedzic T, Pera J, Wnuk M, et al. Serum albumin as a determinant of cortisol release in patients with acute ischemic stroke. Atherosclerosis 2012;221(1):212-14
59. Neidert S, Katan M, Fluri F, et al. Cortisol as a prognostic marker of outcome in acute ischemic cerebrovascular events. Endocrine Abstracts 2009;20:OC3.6
60. Zylberstein DE, Skoog I, Bjorkelund C, et al. Homocysteine levels and lacunar brain infarcts in elderly women: The prospective population study of women in Gothenburg. J Am Geriatr Soc 2008;56(6):1087-91
61. Tascilar N, Ekem S, Aciman E, et al. Hyperhomocysteinemia as an independent risk factor for cardioembolic stroke in the Turkish population. Tohoku J Exp Med 2009;218(4):293-300
62. Feng C, Bai X, Xu Y, et al. Hyperhomocysteinemia associates with small vessel disease more closely than large vessel disease. Int J Med Sci 2013;10(4):408-12
63. Ma Y, Zhao X, Zhang W, et al. Homocysteine and ischemic stroke subtype: A relationship study in Chinese patients. Neurol Res 2010;32(6):636-41
64. Fekih-Mrissa N, Mrad M, Klai S, et al. Methylenetetrahydrofolate reductase (C677T and A1298C) polymorphisms, hyperhomocysteinemia, and ischemic stroke in Tunisian patients. J Stroke Cerebrovasc Dis 2013;22(4):465-9
65. Omrani HQ, Shandiz EE, Qabai M, et al. Hyperhomocysteinemia, folateo and B12 vitamin in Iranian patients with acute ischemic stroke. ARYA Atheroscler 2011; 7(3):97-101
66. Cui R, Moriyama Y, Koike KA, et al. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis 2008;198(2): 412-18
67. Unal E, Mungan S, Bilen S, et al. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. Int J Neurosci 2013;123(8): 532-6
68. Wu XQ, Ding J, Ge AY, et al. Acute phase homocysteine related to severity and outcome of atherothrombotic stroke. Eur J Intern Med 2013;24(4):362-7
69. Ciancarelli I, Di Massimo C, De Amicis D, et al. Evidence of redox unbalance in post-Acute ischemic stroke patients. Curr Neurovasc Res 2012;9(2):85-90
70. Taffi R, Nanetti L, Mazzanti L, et al. Plasma levels of nitric oxide and stroke outcome. J Neurol 2008;255(1):94-8
71. Rajeshwar K, Kaul S, Al-Hazzani A, et al. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: Correlation with clinical outcome. Inflammation 2012; 35(3):978-84
72. Perlstein TS, Pande RL, Creager MA, et al. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008;121(9):781-8
73. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: A prospective study in Korean men and women. Stroke 2009; 40(11):3422-7
74. Pineda S, Bang OY, Saver JL, et al. Association of serum bilirubin with ischemic stroke outcomes. J Stroke Cerebrovasc Dis 2008;17(3):147-52
75. Luo Y, Li JW, Lu ZJ, et al. Serum bilirubin after acute ischemic stroke is associated with stroke severity. Curr Neurovasc Res 2012; 9(2):128-32
76. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-Associated phospholipase A2 (Lp-PLA2): A review of its role and significance as a cardiovascular biomarker. Biomarkers 2012;17(4): 289-302
77. Elkind MS, Tai W, Coates K, et al. Lipoprotein-Associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009;27(1):42-50
78. Thompson A, Gao P, Orfei L, et al. Lp-PLA2 Studies Collaboration. Lipoprotein-Associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010;375: 1536-44
79. Tsai TH, Chen YL, Lin HS, et al. Link between lipoprotein-Associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke. J Atheroscler Thromb 2012;19(6): 523-31
80. Delgado P, Chacón P, Penalba A, et al. Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis 2012;220(2): 532-6
81. Rajeshwar K, Kaul S, Al-Hazzani A, et al. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: Correlation with clinical outcome. Inflammation 2012; 35(3):978-84
82. Topakian R, Strasak AM, Nussbaumer K, et al. Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol 2008; 255(8):1190-6
83. Selvarajah JR, Smith CJ, Hulme S, et al. Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke The North West of England transient ischaemic attack and minor stroke (NORTHSTAR) study. Int J Stroke 2011;6(3):187-94
84. Ladenvall C, Jood K, Blomstrand C, et al. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 2006;37(8):2018-23
85. Kunes P, Holubcova Z, Kolackova M, Krejsek J. Pentraxin 3 (PTX 3): An endogenous modulator of the inflammatory response. Mediators Inflamm 2012;920517
86. Kanbay M, Ikizek M, Solak Y, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 2011;33(4):325-31
87. Ryu WS, Kim CK, Kim BJ, et al. Pentraxin 3: A novel and independent prognostic marker in ischemic stroke. Atherosclerosis 2012;220(2):581-6
88. Welsh P, Barber M, Langhorne P, et al. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009;27(3):247-53
89. Ehrenreich H, Kastner A, Weissenborn K, et al. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med 2011;17(11-12):1306-10
90. Beer C, Blacker D, Bynevelt M, et al. Systemic markers of inflammation are independently associated with S100B concentration: Results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation 2010;7:71
91. Nash DL, Bellolio MF, Stead LG. S100 as a marker of acute brain ischemia: A systematic review. Neurocrit Care 2008; 8(2):301-7
92. Rallidis LS, Zolindaki MG, Vikelis M, et al. Elevated soluble intercellular adhesion molecule-1 levels are associated with poor short-Term prognosis in middle-Aged patients with acute ischaemic stroke. Int J Cardiol 2009;132(2):216-20
93. Wang JY, Zhou DH, Li J, et al. Association of soluble intercellular adhesion molecule 1 with neurological deterioration of ischemic stroke: The Chongqing Stroke Study. Cerebrovasc Dis 2006;21(1-2):67-73
94. Castillo J, Alvarez-Sabín J, Martínez-Vila E, et al. Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study. J Neurol 2009;256(2): 217-24
95. Weiss JB, Eisenhardt SU, Stark GB, et al. MicroRNAs in ischemia-reperfusion injury. Am J Cardiovasc Dis 2012;2(3):237-47
96. Ziu M, Fletcher L, Rana S, et al. Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury. PLoS ONE 2011;6:e14724
97. Cameron Rink and Savita Khanna. MicroRNA in ischemic stroke etiology and pathology. Physiol Genomics 2011;43(10): 521-8
98. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of microRNAs in young stroke patients. PLoS ONE 2009;4: E7689
99. Jeon YJ, Kim OJ, Kim SY, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk. Arterioscler Thromb Vasc Biol 2013;33(2):420-30
100. Zeng L, Liu J, Wang Y, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011;3:1265-72
101. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: A novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66(6):799-808
102. Urwyler SA, Schuetz P, Fluri F, et al. Prognostic value of copeptin: One-year outcome in patients with acute stroke. Stroke 2010;41(7):1564-7
103. Katan M, Nigro N, Fluri F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011;76(6):563-6
104. Dong X, Tao DB, Wang YX, et al. Plasma copeptin levels in Chinese patients with acute ischemic stroke: A preliminary study. Neurol Sci 2013;34(9):1591-5
105. De Marchis GM, Katan M, Weck A, et al. Copeptin adds prognostic information after ischemic stroke: Results from the CoRisk study. Neurology 2013;80(14):1278-86
106. Zhang JL, Yin CH, Zhang Y, et al. Plasma copeptin and long-Term outcomes in acute ischemic stroke. Acta Neurol Scand 2013; 128(6):372-80
107. Tu WJ, Dong X, Zhao SJ, et al. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischemic stroke. J Neuroendocrinol 2013;25(9):771-8